Literature DB >> 19094939

Proton-pump inhibitors in peptic ulcer disease.

Francis K L Chan1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19094939     DOI: 10.1016/S0140-6736(08)61497-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Only full adherence to proton pump inhibitors protects against drug-induced upper gastrointestinal bleeding.

Authors:  Borja Ruiz; Urko Aguirre; Ana Estany-Gestal; Luca Rodella; Pablo Ruiz; Adolfo Figueiras; Alfonso Carvajal; Luisa Ibáñez; Anita Conforti; Marian M de Pancorbo; Xavier Vidal; Luis H Martin; Carmelo Aguirre
Journal:  Eur J Clin Pharmacol       Date:  2018-07-24       Impact factor: 2.953

2.  Clinical evidence of interaction between clopidogrel and proton pump inhibitors.

Authors:  Shoa-Lin Lin; Hui-Min Chang; Chun-Peng Liu; Li-Ping Chou; Jaw-Wen Chan
Journal:  World J Cardiol       Date:  2011-05-26

3.  Evaluation of hemostasis with soft coagulation using endoscopic hemostatic forceps in comparison with metallic hemoclips for bleeding gastric ulcers: a prospective, randomized trial.

Authors:  Seiichiro Arima; Yasuhisa Sakata; Shinichi Ogata; Naoyuki Tominaga; Nanae Tsuruoka; Kotaro Mannen; Ryosuke Shiraishi; Ryo Shimoda; Seiji Tsunada; Hiroyuki Sakata; Ryuichi Iwakiri; Kazuma Fujimoto
Journal:  J Gastroenterol       Date:  2009-12-25       Impact factor: 7.527

Review 4.  Efficacy of proton pump inhibitors for patients with duodenal ulcers: A pairwise and network meta-analysis of randomized controlled trials.

Authors:  Zhan-Hong Hu; Ai-Ming Shi; Duan-Min Hu; Jun-Jie Bao
Journal:  Saudi J Gastroenterol       Date:  2017 Jan-Feb       Impact factor: 2.485

5.  Is administration of proton pump inhibitors in functional dyspepsia worth the risk of developing gastric cancer: a Markov model to bridge the gap between scientific evidence and clinical practice.

Authors:  Efrat Broide; Adi Eindor-Abarbanel; Haim Shirin; Vered Richter; Shay Matalon; Moshe Leshno
Journal:  BMJ Open       Date:  2020-02-12       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.